MEDICAL FACILITIES CORP (DR.CA) Stock Fundamental Analysis
Canada - TSX:DR - CA58457V5036 - Common Stock
14.45 CAD
-0.26 (-1.77%)
Overall DR gets a fundamental rating of 7 out of 10. We evaluated DR against 15 industry peers in the Health Care Providers & Services industry. DR gets an excellent profitability rating and is at the same time showing great financial health properties. DR has a bad growth rate and is valued cheaply. With these ratings, DR could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
In the past year DR was profitable.
DR had a positive operating cash flow in the past year.
Of the past 5 years DR 4 years were profitable.
Each year in the past 5 years DR had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 29.34%, DR belongs to the top of the industry, outperforming 93.33% of the companies in the same industry.
DR has a better Return On Equity (105.57%) than 100.00% of its industry peers.
DR has a Return On Invested Capital of 16.22%. This is amongst the best in the industry. DR outperforms 93.33% of its industry peers.
The Average Return On Invested Capital over the past 3 years for DR is significantly above the industry average of 7.83%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 29.34% | ||
| ROE | 105.57% | ||
| ROIC | 16.22% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
1.3 Margins
DR has a better Profit Margin (28.90%) than 93.33% of its industry peers.
DR's Profit Margin has improved in the last couple of years.
The Operating Margin of DR (14.93%) is better than 100.00% of its industry peers.
DR's Operating Margin has been stable in the last couple of years.
DR's Gross Margin of 65.05% is amongst the best of the industry. DR outperforms 93.33% of its industry peers.
In the last couple of years the Gross Margin of DR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.93% | ||
| PM (TTM) | 28.9% | ||
| GM | 65.05% |
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
DR has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
DR has less shares outstanding than it did 1 year ago.
DR has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, DR has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.28, we must say that DR is in the distress zone and has some risk of bankruptcy.
DR has a Altman-Z score (1.28) which is comparable to the rest of the industry.
DR has a debt to FCF ratio of 1.88. This is a very positive value and a sign of high solvency as it would only need 1.88 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.88, DR belongs to the top of the industry, outperforming 93.33% of the companies in the same industry.
DR has a Debt/Equity ratio of 1.25. This is a high value indicating a heavy dependency on external financing.
DR has a Debt to Equity ratio (1.25) which is in line with its industry peers.
Even though the debt/equity ratio score it not favorable for DR, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.25 | ||
| Debt/FCF | 1.88 | ||
| Altman-Z | 1.28 |
ROIC/WACC1.84
WACC8.81%
2.3 Liquidity
DR has a Current Ratio of 1.58. This is a normal value and indicates that DR is financially healthy and should not expect problems in meeting its short term obligations.
DR has a better Current ratio (1.58) than 100.00% of its industry peers.
DR has a Quick Ratio of 1.48. This is a normal value and indicates that DR is financially healthy and should not expect problems in meeting its short term obligations.
With an excellent Quick ratio value of 1.48, DR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.58 | ||
| Quick Ratio | 1.48 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 193.02% over the past year.
Looking at the last year, DR shows a very negative growth in Revenue. The Revenue has decreased by -37.06% in the last year.
DR shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.59% yearly.
EPS 1Y (TTM)193.02%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%1100%
Revenue 1Y (TTM)-37.06%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-24.84%
3.2 Future
The Earnings Per Share is expected to grow by 10.76% on average over the next years. This is quite good.
DR is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -7.10% yearly.
EPS Next Y32.59%
EPS Next 2Y9.79%
EPS Next 3Y10.76%
EPS Next 5YN/A
Revenue Next Year-21.98%
Revenue Next 2Y-11.46%
Revenue Next 3Y-7.1%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 8.16, the valuation of DR can be described as reasonable.
Based on the Price/Earnings ratio, DR is valued cheaper than 93.33% of the companies in the same industry.
DR's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.34.
A Price/Forward Earnings ratio of 9.09 indicates a reasonable valuation of DR.
100.00% of the companies in the same industry are more expensive than DR, based on the Price/Forward Earnings ratio.
DR's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.43.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.16 | ||
| Fwd PE | 9.09 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DR indicates a rather cheap valuation: DR is cheaper than 100.00% of the companies listed in the same industry.
93.33% of the companies in the same industry are more expensive than DR, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.31 | ||
| EV/EBITDA | 4.17 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of DR may justify a higher PE ratio.
PEG (NY)0.25
PEG (5Y)N/A
EPS Next 2Y9.79%
EPS Next 3Y10.76%
5. Dividend
5.1 Amount
DR has a Yearly Dividend Yield of 2.47%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 3.09, DR pays a bit more dividend than its industry peers.
DR's Dividend Yield is comparable with the S&P500 average which is at 2.36.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.47% |
5.2 History
The dividend of DR decreases each year by -19.91%.
DR has been paying a dividend for at least 10 years, so it has a reliable track record.
DR has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)-19.91%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
7.21% of the earnings are spent on dividend by DR. This is a low number and sustainable payout ratio.
DP7.21%
EPS Next 2Y9.79%
EPS Next 3Y10.76%
TSX:DR (11/12/2025, 7:00:00 PM)
14.45
-0.26 (-1.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.2%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap267.47M
Revenue(TTM)278.37M
Net Income(TTM)80.45M
Analysts42.22
Price Target16.58 (14.74%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.47% |
Yearly Dividend0.36
Dividend Growth(5Y)-19.91%
DP7.21%
Div Incr Years1
Div Non Decr Years4
Ex-Date
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.26%
Min EPS beat(2)-24.98%
Max EPS beat(2)-7.54%
EPS beat(4)1
Avg EPS beat(4)-8.64%
Min EPS beat(4)-41.75%
Max EPS beat(4)39.71%
EPS beat(8)2
Avg EPS beat(8)-39.68%
EPS beat(12)4
Avg EPS beat(12)4.47%
EPS beat(16)6
Avg EPS beat(16)-104.58%
Revenue beat(2)0
Avg Revenue beat(2)-4.32%
Min Revenue beat(2)-4.5%
Max Revenue beat(2)-4.13%
Revenue beat(4)0
Avg Revenue beat(4)-8.01%
Min Revenue beat(4)-18.84%
Max Revenue beat(4)-4.13%
Revenue beat(8)2
Avg Revenue beat(8)-4.04%
Revenue beat(12)3
Avg Revenue beat(12)-2.78%
Revenue beat(16)4
Avg Revenue beat(16)-2.75%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)50.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.16 | ||
| Fwd PE | 9.09 | ||
| P/S | 0.69 | ||
| P/FCF | 3.31 | ||
| P/OCF | 3.12 | ||
| P/B | 2.5 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.17 |
EPS(TTM)1.77
EY12.25%
EPS(NY)1.59
Fwd EY11%
FCF(TTM)4.36
FCFY30.2%
OCF(TTM)4.64
OCFY32.08%
SpS21.09
BVpS5.77
TBVpS-1.62
PEG (NY)0.25
PEG (5Y)N/A
Graham Number15.16
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 29.34% | ||
| ROE | 105.57% | ||
| ROCE | 19.63% | ||
| ROIC | 16.22% | ||
| ROICexc | 21.11% | ||
| ROICexgc | 52.76% | ||
| OM | 14.93% | ||
| PM (TTM) | 28.9% | ||
| GM | 65.05% | ||
| FCFM | 20.69% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
ROICexc(3y)21.7%
ROICexc(5y)18.79%
ROICexgc(3y)53.59%
ROICexgc(5y)43.79%
ROCE(3y)19.81%
ROCE(5y)17.76%
ROICexgc growth 3Y35.06%
ROICexgc growth 5Y23.36%
ROICexc growth 3Y18.42%
ROICexc growth 5Y13.1%
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
F-Score6
Asset Turnover1.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.25 | ||
| Debt/FCF | 1.88 | ||
| Debt/EBITDA | 1.6 | ||
| Cap/Depr | 20.05% | ||
| Cap/Sales | 1.29% | ||
| Interest Coverage | 6.5 | ||
| Cash Conversion | 102.93% | ||
| Profit Quality | 71.58% | ||
| Current Ratio | 1.58 | ||
| Quick Ratio | 1.48 | ||
| Altman-Z | 1.28 |
F-Score6
WACC8.81%
ROIC/WACC1.84
Cap/Depr(3y)47.79%
Cap/Depr(5y)40.36%
Cap/Sales(3y)2.81%
Cap/Sales(5y)2.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)193.02%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%1100%
EPS Next Y32.59%
EPS Next 2Y9.79%
EPS Next 3Y10.76%
EPS Next 5YN/A
Revenue 1Y (TTM)-37.06%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-24.84%
Revenue Next Year-21.98%
Revenue Next 2Y-11.46%
Revenue Next 3Y-7.1%
Revenue Next 5YN/A
EBIT growth 1Y-43.39%
EBIT growth 3Y-6.86%
EBIT growth 5Y-4.85%
EBIT Next Year0.77%
EBIT Next 3Y1.56%
EBIT Next 5YN/A
FCF growth 1Y-0.32%
FCF growth 3Y4.28%
FCF growth 5Y3.38%
OCF growth 1Y-10.39%
OCF growth 3Y3.26%
OCF growth 5Y1.55%
MEDICAL FACILITIES CORP / DR.CA FAQ
What is the fundamental rating for DR stock?
ChartMill assigns a fundamental rating of 7 / 10 to DR.CA.
What is the valuation status for DR stock?
ChartMill assigns a valuation rating of 9 / 10 to MEDICAL FACILITIES CORP (DR.CA). This can be considered as Undervalued.
Can you provide the profitability details for MEDICAL FACILITIES CORP?
MEDICAL FACILITIES CORP (DR.CA) has a profitability rating of 8 / 10.
Can you provide the PE and PB ratios for DR stock?
The Price/Earnings (PE) ratio for MEDICAL FACILITIES CORP (DR.CA) is 8.16 and the Price/Book (PB) ratio is 2.5.
Can you provide the dividend sustainability for DR stock?
The dividend rating of MEDICAL FACILITIES CORP (DR.CA) is 5 / 10 and the dividend payout ratio is 7.21%.